Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 1996

View Archived Issues

Merck & Co. cephalosporins active against MRSA, MRCNS

Lilly claims structurally novel NK1 antagonists

Maxi-K channel modulators from Bristol-Myers Squibb

More antiobesity proteins reported by Lilly

Sandoz claims MAbs against Lewis group antigens for therapeutic use

New class of antibacterial agents discovered by Zeneca

SNX-111 effective in chronic intractable pain

Zonagen allowed further patent coverage for zona pellucida proteins

Marinol promising for geriatric AD

P&U and PRIZM begin ophthalmological collaboration

GBS vaccine proven safe and immunogenic

Research suggests improved treatment for anemia

Glaxo Wellcome to take control of Japanese joint venture

Nyotran progresses towards market introduction

Neose reports promising phase I results for novel antiulcer drug

Milestone achieved in Millennium/Roche research collaboration

Three additional approvals for Rilutek

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....